Sanofi-Aventis Sa (SNY) 49.42 $SNY
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Loaded-Up Alnylam Pharmaceuticals, Inc. Progresses Its Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 12, 6:53PM CST
Alnylam Pharmaceuticals is going to need plenty of cash to get to its goal of having three marketed products and 10 clinical programs in 2020. Fortunately, that's not a major problem at this point. Alnylam ended last year with $882 million in cash...
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82)
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 3:15PM CST
Genzyme, a Sanofi company, today presented data from its Phase 1b clinical study at the Lysosomal Disease Network's WORLD Symposium 2015 in Orlando, Fla. detailing the investigational use of enzyme replacement therapy in the non-neurological manifestations of acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease type
, a lysosomal storage disease caused by genetic mutations that affect the metabolism of sphingomyelin. The Genzyme study evaluated the tolerability and safety of olipudase alfa (recombinant human acid sphingomyelinase) in five adult patients with ASMD.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga(R) (eliglustat) at Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 7:45AM CST
Genzyme, a Sanofi company, today reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga(R) (eliglustat), a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. The results from the studies were presented today at the 11th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme and Voyager Therapeutics collaborate on CNS gene therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:30AM CST
SNY: 49.42 (+0.82)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:40PM CST
Immune Design (IMDZ) is expected to report fourth-quarter 2014 results on Feb 11, 2015 and holds a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00%.
IMDZ: 25.34 (+1.20), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45), SNY: 49.42 (+0.82)
Regeneron Pharmaceuticals Inc. Earnings: All Eyes on Eylea
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 10:35AM CST
Regeneron Pharmaceuticals reported its fourth-quarter numbers before the bell this morning, slightly missing consensus on diluted earnings per share but beating on revenue. The Street expected diluted EPS of $2.82, but the company posted...
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
MannKind Investors: Don't Screw Up The Afrezza Launch
Psycho Analyst - at Seeking Alpha - Tue Feb 10, 9:50AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:28AM CST
Regeneron Pharmaceuticals (REGN) reported fourth-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.16 per share.
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Why MannKind Corporation's Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 09, 4:04PM CST
What: A week after partner Sanofi announced the commercial launch of MannKind Corporation 's inhaled insulin Afrezza, MannKind's shares surged by nearly 10% at one point earlier today before closing with a gain of just under 8%. Source:...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
This Is the Flu Season News We've All Been Waiting For
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 1:18PM CST
As someone who briefly dealt with the flu this season, I can gladly say "good riddance!" While the flu isn't gone by any means -- some 4,600 confirmed cases were reported during week 3, from Jan. 18- Jan 24, according to the Centers for Disease...
SNY: 49.42 (+0.82)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Inhaled Insulin Now Available in the U.S. (Again)
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 06, 8:59AM CST
Diabetics looking to avoid some needle pricks have a new option with Sanofi and MannKind 's Afrezza, which is finally available in pharmacies. It's been a long time coming for the drug-device combination. First rejected by the FDA five years...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:04AM CST
Sanofi (SNY) reported fourth-quarter 2014 business earnings of 87 cents per ADS, 2 cents below the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), AMAG: 41.49 (+0.23), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Loaded-Up Alnylam Pharmaceuticals, Inc. Progresses Its Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 12, 6:53PM CST
Alnylam Pharmaceuticals is going to need plenty of cash to get to its goal of having three marketed products and 10 clinical programs in 2020. Fortunately, that's not a major problem at this point. Alnylam ended last year with $882 million in cash...
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82)
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 3:15PM CST
Genzyme, a Sanofi company, today presented data from its Phase 1b clinical study at the Lysosomal Disease Network's WORLD Symposium 2015 in Orlando, Fla. detailing the investigational use of enzyme replacement therapy in the non-neurological manifestations of acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease type
, a lysosomal storage disease caused by genetic mutations that affect the metabolism of sphingomyelin. The Genzyme study evaluated the tolerability and safety of olipudase alfa (recombinant human acid sphingomyelinase) in five adult patients with ASMD. SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Why Regeneron's Risk-Reward Looks Good Again
DoctoRx - at Seeking Alpha - Thu Feb 12, 12:43PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga(R) (eliglustat) at Lysosomal Disease Network's WORLD Symposium 2015
Business Wire - Thu Feb 12, 7:45AM CST
Genzyme, a Sanofi company, today reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga(R) (eliglustat), a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. The results from the studies were presented today at the 11th Annual Lysosomal Disease Network WORLD Symposium in Orlando, Fla. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals.
SAN: 7.18 (+0.13), SNY: 49.42 (+0.82)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Genzyme and Voyager Therapeutics collaborate on CNS gene therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 7:30AM CST
SNY: 49.42 (+0.82)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:40PM CST
Immune Design (IMDZ) is expected to report fourth-quarter 2014 results on Feb 11, 2015 and holds a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00%.
IMDZ: 25.34 (+1.20), ACT: 285.37 (+3.71), ARIA: 7.35 (+0.45), SNY: 49.42 (+0.82)
Regeneron Pharmaceuticals Inc. Earnings: All Eyes on Eylea
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 10:35AM CST
Regeneron Pharmaceuticals reported its fourth-quarter numbers before the bell this morning, slightly missing consensus on diluted earnings per share but beating on revenue. The Street expected diluted EPS of $2.82, but the company posted...
SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
MannKind Investors: Don't Screw Up The Afrezza Launch
Psycho Analyst - at Seeking Alpha - Tue Feb 10, 9:50AM CST
MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 8:28AM CST
Regeneron Pharmaceuticals (REGN) reported fourth-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.16 per share.
ALNY: 95.54 (+1.67), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Why MannKind Corporation's Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Feb 09, 4:04PM CST
What: A week after partner Sanofi announced the commercial launch of MannKind Corporation 's inhaled insulin Afrezza, MannKind's shares surged by nearly 10% at one point earlier today before closing with a gain of just under 8%. Source:...
SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
This Is the Flu Season News We've All Been Waiting For
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 08, 1:18PM CST
As someone who briefly dealt with the flu this season, I can gladly say "good riddance!" While the flu isn't gone by any means -- some 4,600 confirmed cases were reported during week 3, from Jan. 18- Jan 24, according to the Centers for Disease...
SNY: 49.42 (+0.82)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Inhaled Insulin Now Available in the U.S. (Again)
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 06, 8:59AM CST
Diabetics looking to avoid some needle pricks have a new option with Sanofi and MannKind 's Afrezza, which is finally available in pharmacies. It's been a long time coming for the drug-device combination. First rejected by the FDA five years...
PFE: 34.64 (-0.23), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:04AM CST
Sanofi (SNY) reported fourth-quarter 2014 business earnings of 87 cents per ADS, 2 cents below the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), AMAG: 41.49 (+0.23), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
